This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
septic shock | 990 |
intensive care | 654 |
severe sepsis | 612 |
critically ill | 418 |
care unit | 330 |
ill patients | 322 |
mechanical ventilation | 321 |
organ failure | 296 |
inflammatory response | 272 |
critical care | 270 |
organ dysfunction | 265 |
septic patients | 265 |
endothelial cells | 239 |
apache ii | 221 |
ng ml | 198 |
multiple organ | 198 |
immune response | 188 |
mg kg | 186 |
patients admitted | 184 |
pg ml | 184 |
icu patients | 181 |
nitric oxide | 167 |
lung injury | 156 |
icu admission | 155 |
hospital mortality | 148 |
control group | 148 |
risk factors | 147 |
immune system | 145 |
two groups | 143 |
necrosis factor | 138 |
icu stay | 133 |
significantly higher | 133 |
ml kg | 131 |
acute respiratory | 131 |
mortality rate | 125 |
neonatal sepsis | 122 |
tumor necrosis | 120 |
mean age | 120 |
blood pressure | 117 |
respiratory failure | 115 |
blood flow | 113 |
gene expression | 112 |
respiratory distress | 108 |
renal failure | 108 |
systemic inflammatory | 108 |
critical illness | 107 |
ii score | 106 |
day mortality | 106 |
peripheral blood | 104 |
observational study | 103 |
sofa score | 103 |
cardiac surgery | 102 |
innate immune | 101 |
response syndrome | 101 |
arterial pressure | 100 |
plasma levels | 99 |
cardiac output | 97 |
blood samples | 96 |
significant difference | 96 |
patienten mit | 96 |
distress syndrome | 96 |
trained immunity | 94 |
acute lung | 94 |
clinical trials | 94 |
cytokine production | 90 |
mechanically ventilated | 89 |
significant differences | 89 |
trauma patients | 89 |
care units | 87 |
cardiac arrest | 87 |
statistically significant | 87 |
infl ammatory | 87 |
inflammatory cytokines | 86 |
host response | 86 |
patients undergoing | 85 |
kidney injury | 83 |
mortality rates | 83 |
heart rate | 82 |
mean arterial | 82 |
reactive protein | 82 |
like receptor | 82 |
acute phase | 81 |
arterial blood | 81 |
adult patients | 81 |
replacement therapy | 80 |
present study | 80 |
sepsis patients | 79 |
acute kidney | 78 |
adhesion molecules | 78 |
endothelial cell | 77 |
tidal volume | 74 |
significantly lower | 72 |
logistic regression | 71 |
cohort study | 71 |
university hospital | 70 |
care medicine | 70 |
inflammatory mediators | 69 |
mg dl | 69 |
cardiogenic shock | 69 |
central venous | 69 |
prospective study | 69 |
statistical analysis | 69 |
antibiotic therapy | 68 |
hospital stay | 68 |
whole blood | 68 |
emergency department | 68 |
renal replacement | 68 |
significantly increased | 67 |
patients received | 67 |
bone marrow | 66 |
dendritic cells | 66 |
risk factor | 65 |
icu mortality | 64 |
myocardial infarction | 64 |
healthy volunteers | 64 |
oxygen delivery | 64 |
shock patients | 63 |
cell surface | 62 |
study period | 62 |
consecutive patients | 62 |
patients without | 62 |
blood cultures | 61 |
increased risk | 61 |
surviving sepsis | 61 |
animal models | 61 |
brain injury | 60 |
immune cells | 59 |
sepsis campaign | 59 |
high risk | 58 |
regression analysis | 58 |
ventilated patients | 58 |
body weight | 56 |
ventilator dependence | 56 |
increased mortality | 55 |
significantly reduced | 55 |
negative bacteria | 55 |
clinical trial | 55 |
bacterial infections | 55 |
retrospective study | 55 |
prospective observational | 55 |
activated protein | 55 |
systemic inflammation | 54 |
may also | 54 |
patients receiving | 54 |
reactive oxygen | 54 |
preterm infants | 53 |
sepsis syndrome | 53 |
acute renal | 53 |
hemorrhagic shock | 53 |
cardiac index | 53 |
icu discharge | 53 |
serum levels | 52 |
tissue factor | 52 |
onset sepsis | 52 |
left ventricular | 52 |
high levels | 52 |
adaptive immune | 52 |
fluid resuscitation | 51 |
innate immunity | 51 |
intravenous immunoglobulin | 51 |
mm hg | 50 |
immune responses | 50 |
infectious diseases | 50 |
data suggest | 50 |
hospital discharge | 49 |
host defense | 49 |
mononuclear cells | 49 |
survival rate | 49 |
blood gas | 49 |
high mortality | 48 |
saps ii | 48 |
surgical patients | 48 |
bei patienten | 48 |
adhesion molecule | 48 |
acute myocardial | 48 |
adverse events | 48 |
monoclonal antibody | 48 |
within hours | 47 |
pulmonary artery | 47 |
among patients | 47 |
ml min | 46 |
tissue damage | 46 |
controlled trial | 46 |
patients treated | 45 |
birth weight | 45 |
time points | 45 |
cord uid | 45 |
doc id | 45 |
dysfunction syndrome | 45 |
gram negative | 44 |
drotrecogin alfa | 44 |
growth factor | 43 |
low birth | 43 |
least one | 43 |
cd cd | 43 |
clinical practice | 43 |
reperfusion injury | 43 |
cell types | 43 |
neutropenic patients | 43 |
epithelial cells | 43 |
respiratory rate | 42 |
associated pneumonia | 42 |
escherichia coli | 42 |
may contribute | 42 |
ammatory response | 42 |
lung tissue | 42 |
monoclonal antibodies | 42 |
like receptors | 41 |
oxygen saturation | 41 |
bei der | 41 |
acute pancreatitis | 41 |
systematic review | 41 |
performed using | 41 |
der sepsis | 41 |
important role | 41 |
circular rnas | 40 |
cell death | 40 |
multivariate analysis | 40 |
years old | 40 |
blood cells | 40 |
within days | 40 |
first hours | 40 |
tnf production | 40 |
median age | 40 |
und der | 39 |
preterm neonates | 39 |
heart failure | 39 |
white blood | 39 |
weight infants | 39 |
blood cell | 39 |
fl uid | 39 |
tissue injury | 39 |
cecal ligation | 38 |
traumatic brain | 38 |
pao fio | 38 |
receptor antagonist | 38 |
bacterial infection | 38 |
neutropenic fever | 38 |
renal function | 38 |
may lead | 38 |
inclusion criteria | 38 |
kg min | 38 |
ist die | 38 |
predictive value | 38 |
included patients | 37 |
stimulating factor | 37 |
united states | 37 |
sepsis model | 37 |
higher mortality | 37 |
first days | 37 |
bacterial translocation | 37 |
study group | 37 |
skeletal muscle | 37 |
human sepsis | 37 |
demographic data | 37 |
mit einer | 37 |
negative sepsis | 36 |
recombinant human | 36 |
primary outcome | 36 |
dr expression | 36 |
coronary artery | 36 |
spontaneous breathing | 36 |
bacterial sepsis | 36 |
oxide synthase | 36 |
blood loss | 36 |
venous blood | 36 |
burn injury | 36 |
complement activation | 36 |
results suggest | 36 |
clinical outcome | 36 |
randomized controlled | 36 |
oxidative stress | 36 |
proinfl ammatory | 36 |
care patients | 36 |
multicenter study | 36 |
significant increase | 35 |
urine output | 35 |
und die | 35 |
vascular resistance | 35 |
clinical outcomes | 35 |
infl ammation | 35 |
red blood | 35 |
blood culture | 35 |
oxygen consumption | 35 |
antimicrobial therapy | 35 |
poor outcome | 35 |
pseudomonas aeruginosa | 35 |
significantly decreased | 34 |
blood transfusion | 34 |
long term | 34 |
mast cells | 34 |
results indicate | 34 |
ex vivo | 34 |
oxygen species | 34 |
disease severity | 34 |
respiratory tract | 34 |
one patient | 33 |
risk score | 33 |
inflammatory responses | 33 |
binding protein | 33 |
organ damage | 33 |
serum lactate | 33 |
vascular permeability | 33 |
detect sepsis | 33 |
surgical icu | 33 |
multiple trauma | 33 |
clinical studies | 33 |
significantly different | 33 |
recent studies | 33 |
improved survival | 33 |
plasma concentrations | 33 |
disseminated intravascular | 33 |
major surgery | 33 |
previous studies | 32 |
informed consent | 32 |
elderly patients | 32 |
intravascular coagulation | 32 |
smooth muscle | 32 |
severe trauma | 32 |
sepsis may | 32 |
failure assessment | 32 |
acute physiology | 32 |
experimental sepsis | 31 |
sepsis und | 31 |
proinflammatory cytokines | 31 |
flow cytometry | 31 |
roc curve | 31 |
statistical significance | 31 |
cell adhesion | 31 |
severe acute | 31 |
thermal injury | 31 |
blood mononuclear | 31 |
blood glucose | 31 |
injured patients | 31 |
host immune | 31 |
inflammatory reaction | 31 |
animal studies | 31 |
signal transduction | 31 |
side effects | 31 |
healthy controls | 31 |
three groups | 31 |
ischemia reperfusion | 30 |
factors associated | 30 |
receiver operating | 30 |
plasminogen activator | 30 |
immune function | 30 |
clinical course | 30 |
gabe von | 30 |
cell activation | 30 |
higher risk | 30 |
may play | 29 |
zu einer | 29 |
tissue oxygenation | 29 |
abdominal surgery | 29 |
immune status | 29 |
cytokine levels | 29 |
consensus conference | 29 |
organ injury | 29 |
nosocomial infections | 29 |
liver failure | 29 |
protective effect | 29 |
high dose | 29 |
sepsis diagnosis | 28 |
month period | 28 |
normal saline | 28 |
medical icu | 28 |
abdominal sepsis | 28 |
organ dysfunctions | 28 |
phage therapy | 28 |
herpes simplex | 28 |
increased significantly | 28 |
factor alpha | 28 |
independent risk | 28 |
polymicrobial sepsis | 28 |
time point | 28 |
year period | 28 |
mit einem | 28 |
pressure support | 28 |
vascular endothelial | 28 |
patients suffering | 28 |
independently associated | 28 |
bronchoalveolar lavage | 28 |
peritoneal macrophages | 27 |
early sepsis | 27 |
health care | 27 |
icu length | 27 |
ethics committee | 27 |
right ventricular | 27 |
retrospective analysis | 27 |
septic complications | 27 |
lymph nodes | 27 |
gas exchange | 27 |
tidal volumes | 27 |
complement system | 27 |
measured using | 27 |
low dose | 27 |
patients died | 27 |
early diagnosis | 27 |
metabolic acidosis | 27 |
injury severity | 27 |
risk patients | 27 |
nosocomial infection | 27 |
patient care | 27 |
staphylococcus aureus | 27 |
und damit | 27 |
animal model | 27 |
nervous system | 27 |
international guidelines | 27 |
cytokine release | 26 |
ug ml | 26 |
determine whether | 26 |
overall mortality | 26 |
murine model | 26 |
airway pressure | 26 |
teaching hospital | 26 |
organ system | 26 |
sequential organ | 26 |
study conducted | 26 |
mit der | 26 |
control animals | 26 |
prolonged mechanical | 26 |
significant correlation | 26 |
obese patients | 26 |
septischen schock | 26 |
neutropenic sepsis | 26 |
general icu | 26 |
inflammatory cytokine | 26 |
ards patients | 26 |
burn patients | 26 |
widely used | 26 |
clinical signs | 26 |
phase proteins | 26 |
fluid administration | 25 |
septic syndromes | 25 |
following major | 25 |
human monocytes | 25 |
scoring system | 25 |
wistar rats | 25 |
fatty acids | 25 |
severe septic | 25 |
systemic vascular | 25 |
pulmonary hypertension | 25 |
inhalation injury | 25 |
hydrogen peroxide | 25 |
mouse model | 25 |
barrier function | 25 |
coagulation cascade | 25 |
sepsis sensor | 25 |
surgical intensive | 25 |
postoperative period | 25 |
increased expression | 25 |
type i | 25 |
operating characteristic | 25 |
urinary tract | 25 |
nk cells | 24 |
significant reduction | 24 |
previously reported | 24 |
cardiopulmonary bypass | 24 |
acquired pneumonia | 24 |
ozone therapy | 24 |
sepsis septic | 24 |
ejection fraction | 24 |
adaptive immunity | 24 |
class ii | 24 |
associated molecular | 24 |
viral infections | 24 |
lps challenge | 24 |
simplex virus | 24 |
first time | 24 |
hemodynamic parameters | 24 |
beneficial effects | 24 |
patients presenting | 24 |
early goal | 24 |
durch eine | 24 |
improves survival | 24 |
may result | 24 |
cell lines | 24 |
group i | 24 |
enteral nutrition | 24 |
age years | 24 |
body temperature | 24 |
heat shock | 23 |
mean values | 23 |
positive bacteria | 23 |
tlr agonists | 23 |
confidence interval | 23 |
durch die | 23 |
hospital cardiac | 23 |
auf die | 23 |
emergency room | 23 |
early stage | 23 |
suspected infection | 23 |
may improve | 23 |
admission day | 23 |
crp levels | 23 |
prospective cohort | 23 |
five patients | 23 |
cancer patients | 23 |
hospital admission | 23 |
serum creatinine | 23 |
term neonates | 23 |
molecular mechanisms | 23 |
well known | 23 |
clinical data | 23 |
commonly used | 23 |
human endothelial | 23 |
traumatic injury | 23 |
retrospective cohort | 23 |
membrane oxygenation | 23 |
th cells | 23 |
circular rna | 23 |
patients requiring | 23 |
multiorgan failure | 23 |
compared using | 23 |
lactate levels | 23 |
two patients | 22 |
hospital length | 22 |
transforming growth | 22 |
infectious complications | 22 |
stroke volume | 22 |
significant decrease | 22 |
study showed | 22 |
data indicate | 22 |
time course | 22 |
therapeutic interventions | 22 |
high doses | 22 |
acute illness | 22 |
soluble tnf | 22 |
group received | 22 |
kommt es | 22 |
lower mortality | 22 |
antithrombin iii | 22 |
vena cava | 22 |
medical intensive | 22 |
newborn infants | 22 |
central nervous | 22 |
head injury | 22 |
inflammatory process | 22 |
general hospital | 22 |
immune cell | 22 |
rat model | 22 |
cell function | 22 |
analysis showed | 22 |
parenteral nutrition | 22 |
odontogenic infections | 22 |
von der | 22 |
alveolar macrophages | 22 |
dependence risk | 22 |
continuous infusion | 22 |
lg ml | 22 |
positive correlation | 22 |
cell proliferation | 21 |
preliminary results | 21 |
beneficial effect | 21 |
extracorporeal membrane | 21 |
collected data | 21 |
fluid balance | 21 |
fluid challenge | 21 |
exclusion criteria | 21 |
endotoxic shock | 21 |
major role | 21 |
normal range | 21 |
studied patients | 21 |
einsatz von | 21 |
icu admissions | 21 |
regression model | 21 |
pilot study | 21 |
pulmonary edema | 21 |
cell count | 21 |
mean apache | 21 |
venous pressure | 21 |
surgical trauma | 21 |
wound healing | 21 |
directed therapy | 21 |
auch die | 21 |
mg ml | 21 |
platelet count | 21 |
mixed venous | 21 |
activating factor | 21 |
adult respiratory | 21 |
fungal infections | 21 |
results showed | 21 |
lipid peroxidation | 21 |
intravascular volume | 21 |
invasive mechanical | 21 |
increased levels | 21 |
severity score | 21 |
data collection | 21 |
considered significant | 21 |
septischem schock | 21 |
per day | 21 |
transcription factor | 21 |
ali ards | 20 |
patients developed | 20 |
septic animals | 20 |
ill patient | 20 |
sofa scores | 20 |
kritisch kranken | 20 |
improve survival | 20 |
cd expression | 20 |
cord blood | 20 |
natural killer | 20 |
severely ill | 20 |
serum il | 20 |
blood gases | 20 |
study included | 20 |
kg day | 20 |
intracranial pressure | 20 |
hemodynamic instability | 20 |
patient outcome | 20 |
enrolled patients | 20 |
therapeutic approaches | 20 |
emergency medicine | 20 |
endothelial dysfunction | 20 |
low levels | 20 |
new therapeutic | 20 |
organ failures | 20 |
th day | 20 |
bei einem | 20 |
immune globulin | 20 |
free radicals | 20 |
clinical study | 20 |
higher levels | 20 |
prognostic value | 20 |
odds ratio | 20 |
cardiopulmonary resuscitation | 19 |
risk stratification | 19 |
patients underwent | 19 |
necrotizing enterocolitis | 19 |
one hour | 19 |
baseline characteristics | 19 |
cd cells | 19 |
cell wall | 19 |
invasive ventilation | 19 |
plasma samples | 19 |
may provide | 19 |
increased survival | 19 |
sepsis group | 19 |
pulmonary vascular | 19 |
dependent manner | 19 |
antibiotic treatment | 19 |
significant improvement | 19 |
decision making | 19 |
expression profiles | 19 |
systemic infl | 19 |
apache iii | 19 |
kardiogenem schock | 19 |
die gabe | 19 |
mrna expression | 19 |
infectious disease | 19 |
total body | 19 |
protective effects | 19 |
free radical | 19 |
first day | 19 |
significantly improved | 19 |
treated patients | 19 |
intercellular adhesion | 19 |
treated animals | 19 |
poor prognosis | 19 |
well tolerated | 19 |
patients may | 19 |
tissue perfusion | 19 |
chronic health | 19 |
circulatory failure | 19 |
may help | 19 |
vital signs | 19 |
partial pressure | 19 |
molecular biology | 19 |
assessed using | 19 |
growth hormone | 19 |
sirs criteria | 19 |
clinical significance | 18 |
physiology score | 18 |
ventilatory support | 18 |
blood levels | 18 |
results show | 18 |
septic response | 18 |
significantly correlated | 18 |
lactic acidosis | 18 |
standard deviation | 18 |
inhibitory effect | 18 |
induced lung | 18 |
artery bypass | 18 |
chest pain | 18 |
leading cause | 18 |
surgical procedures | 18 |
pediatric sepsis | 18 |
therapeutic intervention | 18 |
pulse pressure | 18 |
fold increase | 18 |
type ii | 18 |
also found | 18 |
vitro studies | 18 |
cardiac function | 18 |
music therapy | 18 |
tnf receptor | 18 |
central role | 18 |
der patienten | 18 |
mobility group | 18 |
predict mortality | 18 |
carbon monoxide | 18 |
system failure | 18 |
significantly associated | 18 |
major cause | 18 |
organ function | 18 |
bacterial clearance | 18 |
infected patients | 18 |
high concentrations | 18 |
health evaluation | 18 |
average age | 18 |
neutrophil activation | 18 |
venous catheter | 18 |
ammatory cytokines | 18 |
following trauma | 18 |
aki stage | 18 |
per patient | 18 |
activated neutrophils | 18 |
study aimed | 18 |
head trauma | 18 |
investigate whether | 18 |
ang ii | 18 |
study design | 18 |
randomly assigned | 18 |
key role | 18 |
activator inhibitor | 18 |
median time | 18 |
liver disease | 18 |
tumour necrosis | 17 |
base excess | 17 |
im vergleich | 17 |
tnf receptors | 17 |
myeloid cells | 17 |
surface area | 17 |
underlying disease | 17 |
shed blood | 17 |
human septic | 17 |
endothelial damage | 17 |
cardiac dysfunction | 17 |
without sepsis | 17 |
nicht nur | 17 |
receptor expression | 17 |
molecular patterns | 17 |
dna methylation | 17 |
prospective randomized | 17 |
mesenteric lymph | 17 |
days post | 17 |
endothelial permeability | 17 |
determined using | 17 |
abdominal infection | 17 |
sepsis timeline | 17 |
international consensus | 17 |
mortality risk | 17 |
fluid responsiveness | 17 |
capillary permeability | 17 |
cytokine storm | 17 |
prospectively collected | 17 |
bacterial growth | 17 |
high sensitivity | 17 |
icu staff | 17 |
protein synthesis | 17 |
treated group | 17 |
experimental studies | 17 |
may occur | 17 |
pct levels | 17 |
wide range | 17 |
granulocyte colony | 17 |
sepsis study | 17 |
day survival | 17 |
glucose control | 17 |
univariate analysis | 17 |
major trauma | 17 |
normal values | 17 |
marrow transplantation | 17 |
square test | 17 |
lactic acid | 17 |
phagocytic cells | 17 |
highly significant | 17 |
mast cell | 17 |
late sepsis | 17 |
blood products | 17 |
serum samples | 17 |
whitney test | 17 |
female mice | 17 |
ii scores | 17 |
septic patient | 17 |
group box | 17 |
one year | 17 |
werden kann | 17 |
third international | 17 |
intensive insulin | 17 |
fluid infusion | 17 |
myocardial dysfunction | 17 |
tissue hypoxia | 17 |
postoperative day | 17 |
circulating igm | 17 |
positive blood | 17 |
auf eine | 16 |
randomized trial | 16 |
linear regression | 16 |
viral infection | 16 |
real time | 16 |
remains unclear | 16 |
medical patients | 16 |
frequently used | 16 |
hemodynamic changes | 16 |
observation period | 16 |
prognostic factors | 16 |
short term | 16 |
intravenous immunoglobulins | 16 |
clinical presentation | 16 |
proinflammatory cytokine | 16 |
kupffer cells | 16 |
written informed | 16 |
body mass | 16 |
suspected sepsis | 16 |
reports suggest | 16 |
early phase | 16 |
fi ndet | 16 |
initial resuscitation | 16 |
cell line | 16 |
center study | 16 |
group compared | 16 |
life support | 16 |
virus infection | 16 |
male wistar | 16 |
major abdominal | 16 |
oxygen radicals | 16 |
supine position | 16 |
amino acid | 16 |
sepsis remains | 16 |
severity scores | 16 |
may influence | 16 |
non invasive | 16 |
blood sampling | 16 |
clinical setting | 16 |
medical records | 16 |
pulmonary disease | 16 |
critical role | 16 |
controlled trials | 16 |
results demonstrate | 16 |
patients compared | 16 |
artery disease | 16 |
plasma endotoxin | 16 |
peritoneal cavity | 16 |
positive effects | 16 |
patients showed | 16 |
patients required | 16 |
differ significantly | 16 |
inflammatory processes | 16 |
therapeutic approach | 16 |
adverse effects | 16 |
cytokine response | 16 |
common cause | 16 |
insulin therapy | 16 |
single cell | 16 |
endotoxin levels | 16 |
identify patients | 16 |
heart surgery | 16 |
auf der | 16 |
pct level | 16 |
may explain | 16 |
leukocyte antigen | 16 |
immunoglobulin therapy | 16 |
glasgow coma | 16 |
six patients | 16 |
creatinine clearance | 16 |
experimental models | 16 |
patient outcomes | 16 |
scoring systems | 16 |
tnf levels | 16 |
seven patients | 16 |
onset neonatal | 16 |
term mortality | 16 |
acute liver | 16 |
controlled study | 15 |
analysed using | 15 |
studies will | 15 |
acute care | 15 |
septic rats | 15 |
tract infection | 15 |
sepsis definitions | 15 |
significantly elevated | 15 |
smartcare ps | 15 |
broad spectrum | 15 |
therapeutic agents | 15 |
inducible nitric | 15 |
clinically relevant | 15 |
total number | 15 |
chronic disease | 15 |
died within | 15 |
signaling pathways | 15 |
sepsis management | 15 |
inflammatory mediator | 15 |
decreased significantly | 15 |
clinical features | 15 |
microvascular endothelial | 15 |
liver cirrhosis | 15 |
multivariate logistic | 15 |
airway management | 15 |
antimicrobial peptides | 15 |
growth factors | 15 |
way anova | 15 |
studies suggest | 15 |
clinical sepsis | 15 |
transplant recipients | 15 |
tract infections | 15 |
ct scan | 15 |
carbon dioxide | 15 |
dental practice | 15 |
large number | 15 |
cardiac surgical | 15 |
activated macrophages | 15 |
increased susceptibility | 15 |
gold standard | 15 |
nuclear factor | 15 |
expiratory pressure | 15 |
mortality prediction | 15 |
plasma concentration | 15 |
patient safety | 15 |
immune activation | 15 |
rats subjected | 15 |
case report | 15 |
study shows | 15 |
clinical characteristics | 15 |
exact test | 15 |
dawley rats | 15 |
negative predictive | 15 |
neutrophil extracellular | 15 |
patient population | 15 |
low doses | 15 |
sepsis cohort | 15 |
vascular tone | 15 |
fio ratio | 15 |
factor pathway | 15 |
systolic blood | 15 |
septic group | 15 |
und bei | 15 |
als auch | 15 |
placebo group | 15 |
positive end | 15 |
following injury | 15 |
endotracheal tube | 14 |
resistant bacteria | 14 |
des septischen | 14 |
early recognition | 14 |
lipid mediators | 14 |
muscle cells | 14 |
elevated renin | 14 |
two different | 14 |
ko mice | 14 |
kg hr | 14 |
fluid management | 14 |
four patients | 14 |
income countries | 14 |
severe head | 14 |
randomized study | 14 |
pediatric septic | 14 |
treatment group | 14 |
year mortality | 14 |
immunodeficiency virus | 14 |
candida albicans | 14 |
human immunodeficiency | 14 |
fatal outcome | 14 |
neurologic outcome | 14 |
severe ards | 14 |
hemodynamic support | 14 |
icu population | 14 |
macrophage polarization | 14 |
severe infections | 14 |
treatment groups | 14 |
tertiary care | 14 |
extracellular matrix | 14 |
fold higher | 14 |
even though | 14 |
icu setting | 14 |
der regel | 14 |
cell type | 14 |
supportive care | 14 |
burned patients | 14 |
necrotizing pancreatitis | 14 |
immune dysfunction | 14 |
term outcome | 14 |
induced acute | 14 |
groups according | 14 |
pathway inhibitor | 14 |
macrophage activation | 14 |
auch bei | 14 |
group ii | 14 |
willebrand factor | 14 |
cell injury | 14 |
inflammatory diseases | 14 |
kardiogenen schock | 14 |
streptococcus pneumoniae | 14 |
human leukocyte | 14 |
soft tissue | 14 |
primary endpoint | 14 |
elevated levels | 14 |
kardiogenen schocks | 14 |
umbilical vein | 14 |
fi rst | 14 |
statistically different | 14 |
three times | 14 |
higher incidence | 14 |
lg kg | 14 |
patients needed | 14 |
combination therapy | 14 |
body surface | 14 |
sepsis induced | 14 |
ist eine | 14 |
showed significant | 14 |
pulmonary arterial | 14 |
surface expression | 14 |
pivotal role | 14 |
tlr agonist | 14 |
lactate level | 14 |
low cardiac | 14 |
human umbilical | 14 |
early identification | 14 |
analysis revealed | 14 |
interquartile range | 14 |
mv duration | 14 |
protein kinase | 14 |
different types | 14 |
documented infection | 14 |
randomized clinical | 14 |
mediated immunity | 14 |
generally accepted | 14 |
acute organ | 14 |
antigen presentation | 14 |
table shows | 14 |
colony stimulating | 14 |
molecular weight | 14 |
computed tomography | 14 |
lung cancer | 14 |
expression profiling | 14 |
study aims | 14 |
ndet sich | 14 |
retrospective observational | 14 |
breathing trial | 14 |
potential therapeutic | 14 |
three days | 14 |
sepsis induction | 14 |
ml saline | 14 |
coagulation factors | 14 |
mhc class | 14 |
acute brain | 14 |
may increase | 14 |
mucosal barrier | 14 |
baseline values | 14 |
early warning | 14 |
predicted mortality | 14 |
assessment method | 13 |
sham operation | 13 |
blood transfusions | 13 |
control patients | 13 |
myocardial depression | 13 |
endothelial function | 13 |
thrombin generation | 13 |
pediatric patients | 13 |
fluid therapy | 13 |
sepsis biomarkers | 13 |
induced cytokine | 13 |
effector cells | 13 |
surface receptors | 13 |
acute inflammatory | 13 |
sepsis mortality | 13 |
plasmacytoid dendritic | 13 |
cells may | 13 |
levels increased | 13 |
brain barrier | 13 |
first line | 13 |
respiratory syndrome | 13 |
arachidonic acid | 13 |
inflammatory markers | 13 |
phase ii | 13 |
rats treated | 13 |
monocyte deactivation | 13 |
american college | 13 |
severe tbi | 13 |
endothelium dependent | 13 |
patients included | 13 |
brain dysfunction | 13 |
united kingdom | 13 |
significant changes | 13 |
des mods | 13 |
bacterial load | 13 |
piro system | 13 |
recognition receptors | 13 |
und eine | 13 |
probably due | 13 |
patients following | 13 |
patients presented | 13 |
surgery patients | 13 |
undergoing cardiac | 13 |
polymerase chain | 13 |
survival rates | 13 |
von willebrand | 13 |
iu kg | 13 |
patient groups | 13 |
consensus definitions | 13 |
control subjects | 13 |
icu patient | 13 |
patients hospitalized | 13 |
per group | 13 |
severely injured | 13 |
hemodynamic monitoring | 13 |
lps stimulation | 13 |
lps group | 13 |
free days | 13 |
university hospitals | 13 |
cell responses | 13 |
circulating neutrophils | 13 |
ventilator associated | 13 |
i levels | 13 |
gut barrier | 13 |
coagulation system | 13 |
phase response | 13 |
increased cardiac | 13 |
inspired oxygen | 13 |
gestational age | 13 |
lps injection | 13 |
protein levels | 13 |
inflammatory cells | 13 |
findings suggest | 13 |
induced shock | 13 |
treated mice | 13 |
liver transplantation | 13 |
kg bw | 13 |
data collected | 13 |
negative infections | 13 |
contact system | 13 |
experimental animals | 13 |
stem cell | 13 |
traumatic stress | 13 |
subarachnoid hemorrhage | 13 |
total rna | 13 |
complicating acute | 13 |
improve outcomes | 13 |
three different | 13 |
acute coronary | 13 |
der einsatz | 13 |
patients will | 13 |
increased vascular | 13 |
patients using | 13 |
small intestine | 13 |
human volunteers | 13 |
low tidal | 13 |
signifi cantly | 13 |
serum concentrations | 13 |
first week | 13 |
prowess trial | 13 |
medical care | 13 |
bloodstream infection | 13 |
und das | 13 |
positive results | 13 |
common complication | 13 |
capillary leak | 13 |
mitochondrial dysfunction | 13 |
phase iii | 13 |
diabetes mellitus | 13 |
western blotting | 13 |
treated rats | 13 |
cell apoptosis | 13 |
simplified acute | 13 |
percutaneous tracheostomy | 13 |
clinical manifestations | 13 |
coma scale | 13 |
phagocytic activity | 13 |
clinical use | 13 |
adult icu | 13 |
also measured | 12 |
leukocyte adhesion | 12 |
internal jugular | 12 |
two days | 12 |
cox regression | 12 |
hospitalized patients | 12 |
schock und | 12 |
severe systemic | 12 |
postoperative complications | 12 |
nursing care | 12 |
des patienten | 12 |
bacterial pneumonia | 12 |
extracellular traps | 12 |
evaluation ii | 12 |
therapie der | 12 |
myocardial ischemia | 12 |
shock may | 12 |
tnf release | 12 |
physical function | 12 |
time pcr | 12 |
ideal body | 12 |
current study | 12 |
control groups | 12 |
macrophage cell | 12 |
expression levels | 12 |
mass index | 12 |
sepsis onset | 12 |
data analysis | 12 |
healthy subjects | 12 |
cellular injury | 12 |
plasma il | 12 |
group showed | 12 |
drug interactions | 12 |
international sepsis | 12 |
sepsis severity | 12 |
mortality among | 12 |
fecal peritonitis | 12 |
major injury | 12 |
longer hospital | 12 |
vascular smooth | 12 |
bis zu | 12 |
deleterious effects | 12 |
survival time | 12 |
one hundred | 12 |
twice daily | 12 |
high affinity | 12 |
cause mortality | 12 |
high incidence | 12 |
murine sepsis | 12 |
much higher | 12 |
mental status | 12 |
mouse blood | 12 |
lung compliance | 12 |
venous oxygen | 12 |
positive pressure | 12 |
oxygen extraction | 12 |
clinical parameters | 12 |
oxygen free | 12 |
acutely ill | 12 |
endotoxin infusion | 12 |
human studies | 12 |
im septischen | 12 |
lower respiratory | 12 |
ill adults | 12 |
may serve | 12 |
tnf mab | 12 |
icu los | 12 |
arterial oxygen | 12 |
bypass grafting | 12 |
differentially expressed | 12 |
developing countries | 12 |
gastrointestinal tract | 12 |
adverse outcomes | 12 |
uric acid | 12 |
suppressor cells | 12 |
single center | 12 |
pulmonary infection | 12 |
clot microstructure | 12 |
sepsis pathophysiology | 12 |
nursing staff | 12 |
receive either | 12 |
many patients | 12 |
three patients | 12 |
mcg kg | 12 |
prognostic marker | 12 |
hours following | 12 |
natriuretic peptide | 12 |
days later | 12 |
vergleich zu | 12 |
better understanding | 12 |
monocytes macrophages | 12 |
schwerer sepsis | 12 |
coronary angiography | 12 |
ecmo support | 12 |
lps administration | 12 |
following hs | 12 |
several studies | 12 |
dendritic cell | 12 |
every patient | 12 |
recently shown | 12 |
negative bacterial | 12 |
kann die | 12 |
also known | 12 |
mit septischem | 12 |
bacterial challenge | 12 |
surgical wards | 12 |
endothelial activation | 12 |
baseline levels | 12 |
macrophage colony | 12 |
mitochondrial function | 12 |
calculated using | 12 |
nutritional support | 12 |
final outcome | 12 |
following sepsis | 12 |
perfusion pressure | 12 |
bactericidal permeability | 12 |
gender differences | 12 |
rater reliability | 12 |
hoc analysis | 12 |
endotoxin tolerance | 12 |
rv function | 12 |
commercially available | 12 |
herzinsuffi zienz | 12 |
one group | 12 |
blind study | 12 |
electronic health | 12 |
chain reaction | 12 |
medical center | 12 |
clinical criteria | 12 |
converting enzyme | 12 |
pulmonary complications | 12 |
medical students | 12 |
controlled clinical | 12 |
extremely low | 12 |
early stages | 12 |
early detection | 12 |
uid resuscitation | 12 |
lavage fluid | 12 |
sample size | 12 |
pressure variation | 12 |
vascular endothelium | 12 |
least two | 11 |
um die | 11 |
related infection | 11 |
spontaneous circulation | 11 |
icu survivors | 11 |
grant acknowledgment | 11 |
shock trial | 11 |
defined according | 11 |
respiratory system | 11 |
requiring mechanical | 11 |
one episode | 11 |
lung disease | 11 |
ventricular function | 11 |
statistical differences | 11 |
mechanisms involved | 11 |
control mice | 11 |
first step | 11 |
blood lactate | 11 |
linked immunosorbent | 11 |
portal vein | 11 |
vein endothelial | 11 |
pathogen recognition | 11 |
patient group | 11 |
helper cell | 11 |
abscess formation | 11 |
hours post | 11 |
classified according | 11 |
fatty acid | 11 |
also associated | 11 |
care physicians | 11 |
days mortality | 11 |
phase trial | 11 |
early albumin | 11 |
flow rate | 11 |
investigated whether | 11 |
previous study | 11 |
intravenous injection | 11 |
ml lps | 11 |
new onset | 11 |
volume expansion | 11 |
atrial fibrillation | 11 |
patients often | 11 |
protein expression | 11 |
im falle | 11 |
reactive nitrogen | 11 |
intravenous immune | 11 |
also present | 11 |
kgkg min | 11 |
experimental model | 11 |
first group | 11 |
infl ammasome | 11 |
severe traumatic | 11 |
study population | 11 |
current guidelines | 11 |
systemic circulation | 11 |
stress response | 11 |
vasopressor therapy | 11 |
mit dem | 11 |
higher concentrations | 11 |
induced immunosuppression | 11 |
data set | 11 |
prognostic factor | 11 |
clinical research | 11 |
prospectively studied | 11 |
missing data | 11 |
experimental study | 11 |
cell transplantation | 11 |
blood sample | 11 |
data showed | 11 |
blood stream | 11 |
durch den | 11 |
tertiary referral | 11 |
post hoc | 11 |
umbilical cord | 11 |
mit kardiogenem | 11 |
premature infants | 11 |
oxygen supply | 11 |
septic mice | 11 |
circulating levels | 11 |
study entry | 11 |
serum albumin | 11 |
patient demographics | 11 |
cognitive impairment | 11 |
animals treated | 11 |
therapeutic target | 11 |
studies demonstrated | 11 |
pleural effusion | 11 |
es zu | 11 |
recent years | 11 |
increased incidence | 11 |
acute inflammation | 11 |
progenitor cells | 11 |
defi ned | 11 |
kidney disease | 11 |
die prognose | 11 |
single nucleotide | 11 |
chronic dysglycemia | 11 |
endothelial injury | 11 |
apoptotic cell | 11 |
increased plasma | 11 |
age range | 11 |
potential role | 11 |
higher doses | 11 |
endotoxin induced | 11 |
shock protein | 11 |
neonatal bacterial | 11 |
therapeutic strategies | 11 |
gram positive | 11 |
anstieg des | 11 |
post cpb | 11 |
xanthine oxidase | 11 |
chronic liver | 11 |
early postoperative | 11 |
enriched immunoglobulin | 11 |
cell populations | 11 |
significant higher | 11 |
recent study | 11 |
control values | 11 |
two hours | 11 |
chronic renal | 11 |
surgical intervention | 11 |
glucose uptake | 11 |
sepsis incidence | 11 |
currently available | 11 |
term survival | 11 |
positive effect | 11 |
high level | 11 |
rapid response | 11 |
innerhalb der | 11 |
superior vena | 11 |
altman analysis | 11 |
cellular immune | 11 |
respiratory function | 11 |
liver resection | 11 |
plasma tnf | 11 |
median values | 11 |
remains high | 11 |
ventricular dysfunction | 11 |
adrenal insufficiency | 11 |
refractory shock | 11 |
factor receptor | 11 |
control study | 11 |
blood monocytes | 11 |
vitro experiments | 11 |
breast cancer | 11 |
will help | 11 |
stranded rna | 11 |
systemic response | 11 |
intracranial hypertension | 11 |
general anesthesia | 11 |
reduce mortality | 11 |
bl mice | 11 |
inhibitor type | 11 |
mg kgkg | 11 |
four hours | 11 |
microbiologically documented | 11 |
well established | 11 |
defense mechanisms | 11 |
liver function | 11 |
cytokine antagonists | 11 |
human activated | 11 |
spezifi sche | 11 |
useful tool | 11 |
blood volume | 11 |
cardiac arrests | 11 |
secondary outcomes | 11 |
diagnostic performance | 11 |
deficient mice | 11 |
dysregulated host | 11 |
mean duration | 11 |
sepsis bundles | 11 |
correlation coefficient | 11 |
noch nicht | 11 |
male mice | 11 |
jugular vein | 11 |
roc curves | 11 |
oxygen transport | 11 |
pulmonary embolism | 11 |
endotoxin shock | 11 |
correlated well | 11 |
volume resuscitation | 11 |
intestinal ischemia | 11 |
lethal dose | 11 |
comorbidity index | 11 |
may reduce | 10 |
identifying patients | 10 |
tertiary hospital | 10 |
postoperative sepsis | 10 |
ist bei | 10 |
amino acids | 10 |
disease process | 10 |
may reflect | 10 |
der ersten | 10 |
lps induced | 10 |
bei kritisch | 10 |
cell membrane | 10 |
success rate | 10 |
enteral feeding | 10 |
ill septic | 10 |
continuous renal | 10 |
presenting cells | 10 |
cell counts | 10 |
im rahmen | 10 |
community acquired | 10 |
hospital los | 10 |
iu ml | 10 |
ist der | 10 |
inferior vena | 10 |
und sepsis | 10 |
related organ | 10 |
hours later | 10 |
laboratory tests | 10 |
vlbw infants | 10 |
lymphoid cells | 10 |
nine patients | 10 |
valve replacement | 10 |
serum procalcitonin | 10 |
emergency departments | 10 |
clinical observations | 10 |
premature neonates | 10 |
cell dysfunction | 10 |
surface markers | 10 |
total parenteral | 10 |
mediator release | 10 |
data obtained | 10 |
significantly greater | 10 |
case reports | 10 |
kg i | 10 |
hand hygiene | 10 |
coli sepsis | 10 |
life expectancy | 10 |
copy number | 10 |
magic bullets | 10 |
health record | 10 |
organ systems | 10 |
respiratory mechanics | 10 |
hemodynamic variables | 10 |
significant role | 10 |
arterial catheter | 10 |
protective role | 10 |
sepsis decision | 10 |
detection limit | 10 |
mediated immune | 10 |
independent predictors | 10 |
treating sepsis | 10 |
statistically significantly | 10 |
also significantly | 10 |
ist ein | 10 |
decreased mortality | 10 |
haemorrhagic shock | 10 |
adjunctive therapy | 10 |
confusion assessment | 10 |
hepatic dysfunction | 10 |
worse outcome | 10 |
lithium chloride | 10 |
antibiotic use | 10 |
frozen plasma | 10 |
hospital acquired | 10 |
sublingual microcirculation | 10 |
outcome data | 10 |
diagnostic criteria | 10 |
programmed death | 10 |
following surgical | 10 |
defi nitions | 10 |
circulating monocytes | 10 |
host resistance | 10 |
bacterial colonization | 10 |
levels may | 10 |
glucose levels | 10 |
mortality following | 10 |
term infants | 10 |
see table | 10 |
produce cytokines | 10 |
immune defense | 10 |
demographic characteristics | 10 |
ammonia clearance | 10 |
randomised controlled | 10 |
consecutive days | 10 |
febrile neutropenia | 10 |
gas parameters | 10 |
blood sugar | 10 |
single centre | 10 |
dependent relaxation | 10 |
bacterial products | 10 |
four groups | 10 |
epithelial cell | 10 |
remained stable | 10 |
human neutrophils | 10 |
previously described | 10 |
intestinal mucosa | 10 |
increased morbidity | 10 |
serum amyloid | 10 |
hcv patients | 10 |
innovative therapies | 10 |
circulating blood | 10 |
care med | 10 |
extubation failure | 10 |
diagnose sepsis | 10 |
clinical decision | 10 |
animals received | 10 |
complement proteins | 10 |
mass spectrometry | 10 |
tissue oxygen | 10 |
ethical committee | 10 |
endothelial barrier | 10 |
pulse contour | 10 |
clinical management | 10 |
studies indicate | 10 |
complications associated | 10 |
im schock | 10 |
every hours | 10 |
outcome measure | 10 |
linear rna | 10 |
studies using | 10 |
positive organisms | 10 |
first period | 10 |
endotracheal intubation | 10 |
mit sepsis | 10 |
committee approval | 10 |
toward th | 10 |
human blood | 10 |
edema formation | 10 |
human peripheral | 10 |
prospective multicenter | 10 |
medical university | 10 |
sind die | 10 |
per se | 10 |
ecmo circuit | 10 |
die sich | 10 |
zu den | 10 |
und des | 10 |
human spleen | 10 |
higher rate | 10 |
resident macrophages | 10 |
surgical procedure | 10 |
lps binding | 10 |
early administration | 10 |
intubated patients | 10 |
kg body | 10 |
identifi ed | 10 |
ward patients | 10 |
hypertonic saline | 10 |
patients discharged | 10 |
infl uence | 10 |
small bowel | 10 |
shock group | 10 |
immune systems | 10 |
shock proteins | 10 |
may affect | 10 |
also increased | 10 |
neonatal intensive | 10 |
data show | 10 |
artery catheter | 10 |
bei sepsis | 10 |
serum iron | 10 |
neutrophil recruitment | 10 |
host defenses | 10 |
characteristic curve | 10 |
gel electrophoresis | 10 |
ten patients | 10 |
dynamic range | 10 |
fluid removal | 10 |
prone position | 10 |
threatening condition | 10 |
septischen schocks | 10 |
may cause | 10 |
severe forms | 9 |
tissue edema | 9 |
complement cascade | 9 |
picco tm | 9 |
physician collaboration | 9 |
induced tnf | 9 |
tissue plasminogen | 9 |
uncomplicated sepsis | 9 |
healthy individuals | 9 |
results may | 9 |
patient characteristics | 9 |
clostridium difficile | 9 |
cell mediated | 9 |
guidelines recommend | 9 |
abnahme des | 9 |
patients ventilated | 9 |
procoagulant activity | 9 |
cells mm | 9 |
trauma system | 9 |
physical examination | 9 |
anaerobic metabolism | 9 |
hematopoietic stem | 9 |
elective cardiac | 9 |
campaign guidelines | 9 |
polymorphonuclear leukocytes | 9 |
neben der | 9 |
met sepsis | 9 |
took place | 9 |
profi le | 9 |
peripheral vascular | 9 |
respiratory infection | 9 |
cognitive decline | 9 |
increases survival | 9 |
molecule expression | 9 |
feedback function | 9 |
including sepsis | 9 |
hazard ratio | 9 |
genes involved | 9 |
among others | 9 |
mean value | 9 |
healthy donors | 9 |
significant risk | 9 |
severe community | 9 |
viral sepsis | 9 |
immune suppression | 9 |
der notaufnahme | 9 |
phagocytic function | 9 |
piro concept | 9 |
single dose | 9 |
weaning process | 9 |
energy metabolism | 9 |
last years | 9 |
grant acknowledgement | 9 |
ct scans | 9 |
mitochondrial respiration | 9 |
high mobility | 9 |
fibrin deposition | 9 |
hematologic malignancies | 9 |
trial registry | 9 |
taken together | 9 |
apoptotic cells | 9 |
myocardial injury | 9 |
novel therapeutic | 9 |
human neutrophil | 9 |
cortisol levels | 9 |
days following | 9 |
myeloid differentiation | 9 |
target range | 9 |
following hemorrhage | 9 |
immunoglobulin preparation | 9 |
ng gwt | 9 |
lymphocyte apoptosis | 9 |
sepsis models | 9 |
reference method | 9 |
treatment option | 9 |
capillary density | 9 |
early treatment | 9 |
medical school | 9 |
superior mesenteric | 9 |
closely related | 9 |
increased cd | 9 |
analyzed using | 9 |
right ventricle | 9 |
blood plasma | 9 |
mann whitney | 9 |
inflammatory pathways | 9 |
survival group | 9 |
serine protease | 9 |
protease inhibitors | 9 |
recent clinical | 9 |
fluid bolus | 9 |
ventilator settings | 9 |
clinical severity | 9 |
later time | 9 |
heart disease | 9 |
neutrophil elastase | 9 |
genetic polymorphisms | 9 |
transit time | 9 |
type cells | 9 |
one third | 9 |
vivo studies | 9 |
induced changes | 9 |
tyrosine kinase | 9 |
prolonged ventilator | 9 |
pressure ventilation | 9 |
cell receptor | 9 |
using high | 9 |
wedge pressure | 9 |
study including | 9 |
median apache | 9 |
left ventricle | 9 |
mrna levels | 9 |
following lps | 9 |
cellular damage | 9 |
renal dysfunction | 9 |
brain trauma | 9 |
gap junctions | 9 |
admission diagnosis | 9 |
also observed | 9 |
sepsis treatment | 9 |
alternative splicing | 9 |
microvascular blood | 9 |
functional status | 9 |
signifi cant | 9 |
crucial role | 9 |
elevated serum | 9 |
increased serum | 9 |
system may | 9 |
cell transfusion | 9 |
antibiotic prophylaxis | 9 |
fresh frozen | 9 |
ivig preparations | 9 |
animal experiments | 9 |
septic critically | 9 |
squared test | 9 |
including patients | 9 |
increased il | 9 |
patients submitted | 9 |
clinical frailty | 9 |
fi nden | 9 |
dose dependent | 9 |
mechanisms underlying | 9 |
similar results | 9 |
improve outcome | 9 |
following severe | 9 |
reducing mortality | 9 |
mean sem | 9 |
spectrum antibiotics | 9 |
seven days | 9 |
trend toward | 9 |
shockable rhythm | 9 |
bactericidal activity | 9 |
als folge | 9 |
assess whether | 9 |
past years | 9 |
tissue repair | 9 |
specific antibodies | 9 |
first months | 9 |
activated pmns | 9 |
recent data | 9 |
sondern auch | 9 |
weight neonates | 9 |
strongly associated | 9 |
two major | 9 |
neonatal infections | 9 |
human disease | 9 |
amniotic fluid | 9 |
mehr als | 9 |
sepsis diagnostic | 9 |
med doi | 9 |
one hand | 9 |
time period | 9 |
response rate | 9 |
post lps | 9 |
days vs | 9 |
citrate anticoagulation | 9 |
several factors | 9 |
tlr activation | 9 |
increasing protein | 9 |
systemic oxygen | 9 |
phase protein | 9 |
sodium bicarbonate | 9 |
significant association | 9 |
ventricular septal | 9 |
oxygen tension | 9 |
baseline risk | 9 |
hydroxyethyl starch | 9 |
mesenteric artery | 9 |
antimicrobial resistance | 9 |
kg iv | 9 |
infrared spectroscopy | 9 |
respiratory support | 9 |
lymph flow | 9 |
chi square | 9 |
remaining patients | 9 |
small sample | 9 |
adverse outcome | 9 |
und ein | 9 |
albumin infusion | 9 |
group iii | 9 |
transfusion requirements | 9 |
risk assessment | 9 |
underlying diseases | 9 |
internal medicine | 9 |
liver injury | 9 |
neonatal mortality | 9 |
shock complicating | 9 |
zu einem | 9 |
shock treated | 9 |
mixed medical | 9 |
general wards | 9 |
total protein | 9 |
trauma sepsis | 9 |
routine use | 9 |
selected patients | 9 |
pooled plasma | 9 |
better outcomes | 9 |
dysfunction score | 9 |
infected neonates | 9 |
severe infection | 9 |
patients years | 9 |
protein concentration | 9 |
patients suffered | 9 |
crude mortality | 9 |
septic plasma | 9 |
randomized trials | 9 |
positive predictive | 9 |
classifi cation | 9 |
phages may | 9 |
crit care | 9 |
muscle strength | 9 |
two types | 9 |
ventricular ejection | 9 |
future studies | 9 |
induced inflammation | 9 |
ascitic fluid | 9 |
aortic balloon | 9 |
clinical conditions | 9 |
glycemic control | 9 |
hemodynamic effects | 9 |
phase reaction | 9 |
acinetobacter baumannii | 9 |
may represent | 9 |
intestinal motility | 9 |
results obtained | 9 |
low concentrations | 9 |
immune functions | 9 |
intraabdominal pressure | 9 |
synthesis inhibitor | 9 |
related mortality | 9 |
median value | 9 |
aki patients | 9 |
bacterial lipopolysaccharide | 9 |
respiratory burst | 9 |
produce il | 9 |
host inflammatory | 9 |
purpura fulminans | 9 |
experimental animal | 9 |
associated costs | 9 |
elective surgery | 9 |
surgical complications | 9 |
prothrombin time | 9 |
poor outcomes | 9 |
lysosomal enzymes | 9 |
patients whose | 9 |
different groups | 9 |
microbial invasion | 9 |
nosocomial sepsis | 9 |
icp monitoring | 9 |
hemoperfusion cartridge | 9 |
inotropic support | 9 |
neurological complications | 9 |
human plasma | 9 |
charlson comorbidity | 9 |
delayed hypersensitivity | 9 |
primary care | 8 |
enriched immunoglobulins | 8 |
chronic diseases | 8 |
eol care | 8 |
available evidence | 8 |
sepsis using | 8 |
hematological malignancies | 8 |
new method | 8 |
immune deficiency | 8 |
soluble icam | 8 |
kritisch kranker | 8 |
csf treatment | 8 |
stage renal | 8 |
pulmonary oedema | 8 |
lung water | 8 |
aortic endothelial | 8 |
also recorded | 8 |
arterial hypotension | 8 |
high tidal | 8 |
received either | 8 |
ecmo patients | 8 |
care doi | 8 |
bacterial cell | 8 |
inpatient care | 8 |
chronic kidney | 8 |
conducted using | 8 |
hypovolemic shock | 8 |
matrix proteins | 8 |
percutaneous coronary | 8 |
oxygen partial | 8 |
infusion rate | 8 |
polymorphonuclear neutrophils | 8 |
female bmdms | 8 |
antimicrobial treatment | 8 |
expiratory flow | 8 |
gene transcription | 8 |
reduced expression | 8 |
multiorgan dysfunction | 8 |
therapeutic effect | 8 |
splenic macrophages | 8 |
icu nurses | 8 |
new biomarkers | 8 |
kann durch | 8 |
immunosorbent assay | 8 |
coli endotoxin | 8 |
cell viability | 8 |
increased pulmonary | 8 |
schock ist | 8 |
systemic lupus | 8 |
inhibitory factor | 8 |
factor expression | 8 |
neonatal infection | 8 |
daily living | 8 |
will need | 8 |
cardiovascular dysfunction | 8 |
shock states | 8 |
kann es | 8 |
neutrophil count | 8 |
caloric intake | 8 |
dysfunction failure | 8 |
producing cells | 8 |
superoxide dismutase | 8 |
confidence intervals | 8 |
samples taken | 8 |
promising results | 8 |
killer cells | 8 |
hepatic failure | 8 |
minute ventilation | 8 |
tight glucose | 8 |
significantly less | 8 |
induced trained | 8 |
splice site | 8 |
serum igm | 8 |
myocardial function | 8 |
ist das | 8 |
significant increases | 8 |
new interventions | 8 |
categorical data | 8 |
monocyte il | 8 |
developed septic | 8 |
sepsis sepsis | 8 |
good correlation | 8 |
group without | 8 |
secondary care | 8 |
postoperative infection | 8 |
clinical syndrome | 8 |
patients scheduled | 8 |
nitrite nitrate | 8 |
infarction complicated | 8 |
ats sis | 8 |
cells produce | 8 |
bedside review | 8 |
mental health | 8 |
syndrome coronavirus | 8 |
abdominal aortic | 8 |
serum tnf | 8 |
bei kardiogenem | 8 |
therapeutic hypothermia | 8 |
kg ideal | 8 |
rat liver | 8 |
human endotoxemia | 8 |
sccm esicm | 8 |
effi cacy | 8 |
plasma level | 8 |
patients affected | 8 |
mortality compared | 8 |
new therapies | 8 |
pediatric population | 8 |
matrix metalloproteinase | 8 |
accp ats | 8 |
negative bacteremia | 8 |
high dependency | 8 |
global mortality | 8 |
lung epithelial | 8 |
mg iv | 8 |
tight junction | 8 |
using spss | 8 |
medical staff | 8 |
general population | 8 |
blood bank | 8 |
oxygen utilization | 8 |
cardiac slices | 8 |
mortality benefit | 8 |
blood group | 8 |
curve analysis | 8 |
one point | 8 |
depressive mood | 8 |
definitions conference | 8 |
room temperature | 8 |
median icu | 8 |
laboratory findings | 8 |
venous ecmo | 8 |
patients diagnosed | 8 |
will provide | 8 |
unit patients | 8 |
study fluids | 8 |
septischer schock | 8 |
shear stress | 8 |
analysis demonstrated | 8 |
control rats | 8 |
stimulation test | 8 |
surviving patients | 8 |
related factors | 8 |
end points | 8 |
clot formation | 8 |
bacterial toxins | 8 |
routinely used | 8 |
acquired infection | 8 |
without delay | 8 |
mean time | 8 |
severe injury | 8 |
onset severe | 8 |
systolic pressure | 8 |
adult icus | 8 |
po fio | 8 |
support ventilation | 8 |
also evaluated | 8 |
gut flora | 8 |
second day | 8 |
bacteraemic episodes | 8 |
patients met | 8 |
evaluated using | 8 |
chart review | 8 |
differential expression | 8 |
structural empowerment | 8 |
manual hyperinflation | 8 |
wide variety | 8 |
activation markers | 8 |
und septischem | 8 |
studies showed | 8 |
promoter region | 8 |
hiv aids | 8 |
early onset | 8 |
stress doses | 8 |
negative correlation | 8 |
chronic critical | 8 |
second group | 8 |
facs analysis | 8 |
cmv infection | 8 |
false positive | 8 |
tg kg | 8 |
task force | 8 |
dead space | 8 |
although many | 8 |
predictive values | 8 |
cytokine profile | 8 |
cardiac failure | 8 |
patient samples | 8 |
abnormal rv | 8 |
better outcome | 8 |
immunoglobulin replacement | 8 |
urea nitrogen | 8 |
continuous intravenous | 8 |
bei den | 8 |
nk cell | 8 |
vascular occlusion | 8 |
mitralinsuffi zienz | 8 |
cell response | 8 |
trend towards | 8 |
severe respiratory | 8 |
fourteen patients | 8 |
studies show | 8 |
median number | 8 |
patients infected | 8 |
patients enrolled | 8 |
indian subset | 8 |
vascular bed | 8 |
macrophage migration | 8 |
phase i | 8 |
magnesium sulphate | 8 |
different doses | 8 |
full thickness | 8 |
much lower | 8 |
persistent pulmonary | 8 |
double blind | 8 |
oleic acid | 8 |
clinical evidence | 8 |
sepsis date | 8 |
prostaglandin synthesis | 8 |
der wahl | 8 |
circulating il | 8 |
relative risk | 8 |
second study | 8 |
cognitive dysfunction | 8 |
spleen cells | 8 |
ventilator days | 8 |
chronic inflammatory | 8 |
resistant enterococcus | 8 |
illness polyneuromyopathy | 8 |
human il | 8 |
pressure monitoring | 8 |
lung regions | 8 |
main cause | 8 |
sich bei | 8 |
classifi ed | 8 |
resuscitation bundle | 8 |
pediatric intensive | 8 |
general surgery | 8 |
care admission | 8 |
study suggests | 8 |
binding lectin | 8 |
hemodynamic response | 8 |
widespread use | 8 |
lv function | 8 |
systolic function | 8 |
intraperitoneal injection | 8 |
early enteral | 8 |
sepsis development | 8 |
carotid artery | 8 |
impaired oxygen | 8 |
severity scoring | 8 |
whole body | 8 |
allogeneic blood | 8 |
elevated plasma | 8 |
shock due | 8 |
log rank | 8 |
organ perfusion | 8 |
retrospectively reviewed | 8 |
initially treated | 8 |
showed significantly | 8 |
interferon gamma | 8 |
remained unchanged | 8 |
helper cells | 8 |
stress ulcers | 8 |
perceived hopelessness | 8 |
emergency surgery | 8 |
vasopressor exposure | 8 |
may include | 8 |
authors declare | 8 |
first postoperative | 8 |
obstructive pulmonary | 8 |
coagulation activation | 8 |
review board | 8 |
consecutive adult | 8 |
improving outcomes | 8 |
interstitial lung | 8 |
antibiotic resistance | 8 |
chronic obstructive | 8 |
radical production | 8 |
autologous blood | 8 |
therapeutic potential | 8 |
graft infection | 8 |
negative blood | 8 |
survive sepsis | 8 |
des herzens | 8 |
wallis test | 8 |
multiple comparisons | 8 |
hour survival | 8 |
refractory septic | 8 |
ct head | 8 |
available data | 8 |
cell population | 8 |
lps receptor | 8 |
bacterial endotoxin | 8 |
ammonia levels | 8 |
prospective studies | 8 |
damit eine | 8 |
multidisciplinary team | 8 |
die diagnose | 8 |
protective immunity | 8 |
host responses | 8 |
authors concluded | 8 |
germany critical | 8 |
jedoch nicht | 8 |
nos inhibitor | 8 |
septic state | 8 |
reduced mortality | 8 |
intravenous infusion | 8 |
inflammatory properties | 8 |
adversely affect | 8 |
gastric emptying | 8 |
aber auch | 8 |
esicm accp | 8 |
sepsis risk | 8 |
ml respectively | 8 |
renal impairment | 8 |
autoimmune diseases | 8 |
culture medium | 8 |
serum pct | 8 |
two dimensional | 8 |
patients developing | 8 |
time interval | 8 |
listeria monocytogenes | 8 |
function following | 8 |
lung protective | 8 |
age group | 8 |
preclinical studies | 8 |
intravenous administration | 8 |
diastolic function | 8 |
study patients | 8 |
blood coagulation | 8 |
circulating cytokines | 8 |
repeated measures | 8 |
ros generation | 8 |
relatively low | 8 |
independent predictor | 8 |
vein thrombosis | 8 |
sepsis also | 8 |
observational cohort | 8 |
das auftreten | 8 |
acute necrotizing | 8 |
operative day | 8 |
severe brain | 8 |
acute circulatory | 8 |
nden sich | 8 |
alcohol abuse | 8 |
mit schwerer | 8 |
data base | 8 |
microvascular permeability | 8 |
synthase inhibitor | 8 |
protein level | 8 |
severe hypoxemia | 8 |
tlr signaling | 8 |
energy expenditure | 8 |
protease inhibitor | 8 |
sex ratio | 8 |
macrophage inflammatory | 8 |
sis international | 8 |
measured daily | 8 |
extracorporeal circulation | 8 |
programmed cell | 8 |
gene products | 8 |
patients meeting | 8 |
defi nition | 8 |
continuous data | 8 |
vasoactive drugs | 8 |
negative organisms | 8 |
clinical evaluation | 8 |
multivariable logistic | 8 |
pain management | 8 |
may predict | 8 |
data regarding | 8 |
icu care | 8 |
lymphocyte function | 8 |
solid organ | 8 |
first study | 8 |
possible role | 8 |
pulsatility index | 8 |
early mortality | 8 |
group treated | 8 |
vitro stimulation | 8 |
inflammatory protein | 8 |
endotracheal suctioning | 8 |
epidemiological data | 8 |
bacteraemic sepsis | 8 |
excluded patients | 8 |
clotting factors | 8 |
one patients | 8 |
immune mechanisms | 8 |
blood leukocytes | 8 |
ventilation strategy | 8 |
tbi patients | 8 |
endothelial surface | 8 |
late phase | 8 |
cd antigen | 7 |
standard therapy | 7 |
congestive heart | 7 |
serious adverse | 7 |
des kardiogenen | 7 |
durch einen | 7 |
negative infection | 7 |
gapdh activity | 7 |
normal human | 7 |
digit threat | 7 |
well characterized | 7 |
mesothelial cells | 7 |
frequently associated | 7 |
intracellular pathogens | 7 |
low risk | 7 |
test whether | 7 |
inflammatory disorders | 7 |
showed higher | 7 |
microvascular perfusion | 7 |
practice parameters | 7 |
th th | 7 |
potential benefits | 7 |
adaptive response | 7 |
patient ventilator | 7 |
volume controlled | 7 |
weaning failure | 7 |
induced organ | 7 |
uk sepsis | 7 |
tissue samples | 7 |
antigen presenting | 7 |
variables associated | 7 |
derived suppressor | 7 |
many years | 7 |
required mechanical | 7 |
factors may | 7 |
nitrate concentrations | 7 |
obese icu | 7 |
markedly reduced | 7 |
im kardiogenen | 7 |
following hemorrhagic | 7 |
years ago | 7 |
gastric cancer | 7 |
alphaiib beta | 7 |
term outcomes | 7 |
anticoagulant activity | 7 |
endotoxin release | 7 |
ml hr | 7 |
unrestricted policy | 7 |
homologous blood | 7 |
hepatic function | 7 |
prospective clinical | 7 |
help us | 7 |
decreased production | 7 |
andexanet alfa | 7 |
physiological parameters | 7 |
und einem | 7 |
induced apoptosis | 7 |
protected mice | 7 |
medical personnel | 7 |
septic encephalopathy | 7 |
toxic shock | 7 |
verbesserung der | 7 |
steady state | 7 |
care services | 7 |
scrub typhus | 7 |
statistical difference | 7 |
multiple logistic | 7 |
maintain adequate | 7 |
also noted | 7 |
study protocol | 7 |
arterial hypertension | 7 |
microbial products | 7 |
important mediator | 7 |
surgical stress | 7 |
antibacterial therapy | 7 |
auf den | 7 |
negative effects | 7 |
inotrope wirkung | 7 |
sepsis score | 7 |
common practice | 7 |
activated monocytes | 7 |
continuous veno | 7 |
null mice | 7 |
nur bei | 7 |
rna splicing | 7 |
frequent complication | 7 |
source control | 7 |
phase clinical | 7 |
oxygen therapy | 7 |
capillary refi | 7 |
multicenter trial | 7 |
transfusion requirement | 7 |
spontaneously breathing | 7 |
klebsiella spp | 7 |
cytokine secretion | 7 |
last decade | 7 |
alveoloseptal thickening | 7 |
medical treatment | 7 |
cytokines including | 7 |
greater risk | 7 |
es zur | 7 |
evidence based | 7 |
regulatory role | 7 |
descriptive statistics | 7 |
treat patients | 7 |
eu ml | 7 |
dependency unit | 7 |
procoagulant state | 7 |
dysfunktion des | 7 |
der septischen | 7 |
lps lethality | 7 |
fractal dimension | 7 |
consecutively admitted | 7 |
citrate crrt | 7 |
data demonstrate | 7 |
sepsis early | 7 |
data suggests | 7 |
proximal tubular | 7 |
mortality remains | 7 |
im wesentlichen | 7 |
des herzindex | 7 |
different stages | 7 |
high prevalence | 7 |
protects mice | 7 |
lung inflammation | 7 |
intravital microscopy | 7 |
receiving mechanical | 7 |
within minutes | 7 |
receptor signaling | 7 |
levels increase | 7 |
currently used | 7 |
will also | 7 |
cytokine concentrations | 7 |
significantly attenuated | 7 |
high morbidity | 7 |
habp vabp | 7 |
cd ro | 7 |
lymphoid tissue | 7 |
perioperative period | 7 |
rats received | 7 |
sepsis trust | 7 |
bl sccr | 7 |
primary objective | 7 |
bacterial overgrowth | 7 |
inflammatory reactions | 7 |
emergency care | 7 |
age groups | 7 |
ill medical | 7 |
corticotropin stimulation | 7 |
tissue trauma | 7 |
north america | 7 |
negative bacilli | 7 |
i receptor | 7 |
wird durch | 7 |